Clinical Trials
2 trialsNCT07585747 2026-05-14
CUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04989621 2026-04-23
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Phase 2 Recruiting